Enhertu Approved in the EU as Adjuvant Treatment for HER2 Positive Early Breast Cancer

The European Commission approved Daiichi Sankyo and AstraZeneca’s Enhertu as an adjuvant treatment for patients with HER2-positive early breast cancer who have residual disease after neoadjuvant therapy. It is the drug’s first EU approval in a curative-intent early breast cancer setting, based on late-stage trial data showing a significant reduction in the risk of recurrence or death. AstraZeneca will pay Daiichi Sankyo a $75 million milestone payment following the approval.